Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastic Drugs
- Alkylating Antineoplastics
- Antineoplastic Alkylating Agents
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Agents, Antineoplastic
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Int J Mol Sci. 2023 Apr 27; 24(9).
-
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 06 01; 28(11):2306-2312.
-
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
-
Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078.
-
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Rev Anticancer Ther. 2020 04; 20(sup1):15-28.
-
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
-
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
-
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017 Oct 01; 19(10):1380-1390.
-
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.